ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 222 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,273,000 | -51.4% | 35,749 | -37.0% | 0.00% | -100.0% |
| Q2 2023 | $2,618,000 | +15.0% | 56,735 | -0.1% | 0.00% | 0.0% |
| Q1 2023 | $2,277,000 | +1055.8% | 56,778 | +1236.0% | 0.00% | – |
| Q4 2022 | $197,000 | +27.1% | 4,250 | +13.0% | 0.00% | – |
| Q3 2022 | $155,000 | -62.2% | 3,760 | -45.1% | 0.00% | – |
| Q2 2022 | $410,000 | -22.1% | 6,852 | -5.5% | 0.00% | – |
| Q1 2022 | $526,000 | -28.3% | 7,251 | -16.9% | 0.00% | – |
| Q4 2021 | $734,000 | +2.1% | 8,727 | +9.3% | 0.00% | – |
| Q3 2021 | $719,000 | -76.4% | 7,988 | -75.0% | 0.00% | -100.0% |
| Q2 2021 | $3,052,000 | +319.8% | 32,006 | +401.7% | 0.00% | – |
| Q1 2021 | $727,000 | +6.0% | 6,379 | +28.6% | 0.00% | – |
| Q4 2020 | $686,000 | +253.6% | 4,961 | +109.8% | 0.00% | – |
| Q3 2020 | $194,000 | +104.2% | 2,365 | +95.6% | 0.00% | – |
| Q2 2020 | $95,000 | +1087.5% | 1,209 | +598.8% | 0.00% | – |
| Q1 2020 | $8,000 | -92.5% | 173 | -93.2% | 0.00% | – |
| Q4 2019 | $107,000 | +64.6% | 2,531 | +64.5% | 0.00% | – |
| Q3 2019 | $65,000 | +441.7% | 1,539 | +650.7% | 0.00% | – |
| Q2 2019 | $12,000 | -85.9% | 205 | -83.2% | 0.00% | – |
| Q1 2019 | $85,000 | +102.4% | 1,223 | +28.1% | 0.00% | – |
| Q4 2018 | $42,000 | -75.6% | 955 | -57.6% | 0.00% | – |
| Q3 2018 | $172,000 | +11.0% | 2,255 | +11.4% | 0.00% | – |
| Q2 2018 | $155,000 | +868.8% | 2,025 | +526.9% | 0.00% | – |
| Q1 2018 | $16,000 | -99.9% | 323 | -99.9% | 0.00% | -100.0% |
| Q4 2017 | $12,608,000 | +2.9% | 271,845 | +18.1% | 0.01% | 0.0% |
| Q3 2017 | $12,253,000 | -12.0% | 230,087 | +2.6% | 0.01% | -14.3% |
| Q2 2017 | $13,929,000 | +846.9% | 224,261 | +933.2% | 0.01% | +600.0% |
| Q1 2017 | $1,471,000 | -86.5% | 21,705 | -86.0% | 0.00% | -83.3% |
| Q4 2016 | $10,885,000 | -6.7% | 154,804 | -5.9% | 0.01% | 0.0% |
| Q3 2016 | $11,672,000 | +78.9% | 164,538 | +23.3% | 0.01% | +50.0% |
| Q2 2016 | $6,526,000 | -10.7% | 133,424 | +15.5% | 0.00% | -20.0% |
| Q1 2016 | $7,311,000 | +182675.0% | 115,483 | +360784.4% | 0.01% | – |
| Q4 2015 | $4,000 | -97.7% | 32 | -98.2% | 0.00% | – |
| Q3 2015 | $173,000 | -59.8% | 1,798 | -57.2% | 0.00% | – |
| Q2 2015 | $430,000 | -38.7% | 4,200 | -62.8% | 0.00% | – |
| Q1 2015 | $702,000 | – | 11,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |